Alzheimer’s disease (AD), a heterogeneous, neurodegenerative condition with an insidious onset and slow progression, is the leading cause of disability and morbidity as well as the sixth-leading cause of death in the United States. Diagnoses is often challenging, and multimodal imaging strategies and other novel and emerging biomarkers can aid in differential diagnosis. Currently only symptomatic therapies are available, but recent clinical trials investigating disease-modifying therapies (DMTs) that could slow or reverse the progression of AD have shown great promise.
CME Outfitters is pleased to offer accredited CME/CE activities providing expert-led education on the pathogenesis of AD, current diagnostic criteria and guidelines for AD management, recent advances in the development of AD biomarkers, and the latest clinical evidence on emerging therapies.
In the second activity of this CME Outfitters BriefCase series, expert faculty will utilize a patient case format to illustrate approaches for diagnosing AD, implementing treatment that includes MDT care, and practicing SDM to achieve optimal patient outcomes.
In the first activity of this CME Outfitters BriefCase series, expert faculty will utilize a patient case format to illustrate utilization of current and emerging screening and diagnostic tools in diverse populations for early detection of AD, as well as integration of culturally sensitive patient and caregiver education strategies to improve SDM on brain health and AD management with patients.
In this CME Outfitters Podcast, expert faculty will discuss utilization of current and emerging screening and diagnostic tools in diverse populations for detection of AD early in the disease course; integration of culturally sensitive patient and caregiver education strategies to improve shared decision-making on brain health and/or AD management with patients; and implementation of MDT care when treating patients with AD.
In this second installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will evaluate the latest data from ATT clinical trials and discuss strategies for identifying appropriate patients based on both pathological and clinical characteristics to ensure timely and optimal management of patients with early symptomatic AD.
In this first installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will present the latest information on the neuropathological changes associated with AD, their relevance to the cognitive and functional decline of early AD, as well as the role of phosphorylated tau biomarkers as early indicators of both amyloid and tau accumulation.
The first episode of this CMEO BriefCase series focuses on a patient case that requires differentiating ARIA from other conditions with a similar presentation in the emergency care setting, highlighting ARIA-related symptoms, listing other clinical manifestations of ARIA as described in clinical trials, and reviewing contraindicated medications for patients receiving an ATT.
The third and final episode of this CMEO BriefCase series focuses on a case involving a patient on an ATT presenting to the emergency department (ED), highlighting ED protocols to streamline care for patients with severe ARIA, recommendations for treatment and supportive care measures, global resources for guidance as the ATT landscape expands, management of ARIA according to best guidance, and communication with ATT-treating clinicians and radiologists.
The second episode of this CMEO BriefCase series focuses on a patient case that demonstrates real-world challenges such as obtainment of an accurate medical history, imaging needs and interpretations, and what to do if magnetic resonance imaging (MRI) is not accessible.
